Y-mabs Therapeutics Stock Fair Value – Y-mAbs Therapeutics Joins Nasdaq Biotechnology Index
December 16, 2023
🌥️Trending News
Y-MABS ($NASDAQ:YMAB): Y-mAbs Therapeutics recently announced that it will be joining the Nasdaq Biotechnology Index, a select group of biotechnology and pharmaceutical companies listed on the Nasdaq stock exchange. Y-mAbs Therapeutics is a biopharmaceutical company focused on developing advanced antibody-based treatments for pediatric cancer. The company is dedicated to creating innovative therapies for children and young adults fighting cancer. They have a diverse portfolio of therapeutic programs, including Bolero-3, a bispecific immuno-oncology antibody for the treatment of neuroblastoma.
Inclusion in the Nasdaq Biotechnology Index marks an important development in Y-mAbs Therapeutics’ growth story, as it demonstrates the company’s commitment to furthering its goals and strengthening its presence in the field of pediatric cancer therapeutics. It also allows investors to easily track their performance and access investment opportunities in the biotechnology industry. With its inclusion in the index, Y-mAbs Therapeutics can now benefit from increased visibility among investors and potential partners.
Share Price
On Thursday, Y-MABS THERAPEUTICS had a successful day on the stock market, as their stock opened at $7.0 and closed at $6.9, up by 0.9% from last closing price of 6.8. This exciting event marks an important milestone for the company, as they have been officially added to the Nasdaq Biotechnology Index. Y-MABS THERAPEUTICS is a biopharmaceutical company focused on developing innovative antibody-based treatments for cancer. This exciting addition to the Nasdaq Biotechnology Index is a testament to their dedication to making cutting edge treatments to fight cancer and other diseases.
This move also signals that Y-MABS THERAPEUTICS is gaining traction as an up-and-coming biotechnology company. With the recent success of their stock movement, investors are more likely to take notice of the company and its potential for future growth. This is only the beginning, and Y-MABS THERAPEUTICS has much more potential for success in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Y-mabs Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 92.9 | -19.28 | -20.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Y-mabs Therapeutics. More…
| Operations | Investing | Financing |
| -27.86 | 0 | 0 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Y-mabs Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 128.88 | 28.73 | 2.3 |
Key Ratios Snapshot
Some of the financial key ratios for Y-mabs Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -25.4% |
| FCF Margin | ROE | ROA |
| -30.0% | -14.4% | -11.5% |
Analysis – Y-mabs Therapeutics Stock Fair Value
GoodWhale is the perfect tool for investors to analyze Y-MABS THERAPEUTICS‘s fundamentals. Through our proprietary Valuation Line, we have calculated that the fair value of Y-MABS THERAPEUTICS share is around $37.7. Unfortunately, Y-MABS THERAPEUTICS stock is currently trading at $6.9, which is an incredible 81.7% undervalued. This means there is a huge opportunity for investors to buy Y-MABS THERAPEUTICS stock and potentially get a large return on their investment. More…
Peers
The company’s lead product candidate, naxitamab, is in clinical development for the treatment of neuroblastoma, a rare and aggressive pediatric cancer. Y-mAbs Therapeutics Inc’s other product candidates are in clinical and preclinical development for the treatment of solid tumors and blood cancers. The company’s competitors include BioAtla Inc, Adagio Therapeutics Inc, and Orphazyme AS.
– BioAtla Inc ($NASDAQ:BCAB)
BioAtla Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immuno-oncology agents. The company’s market cap as of 2022 is 357.65M and its ROE is -41.59%. BioAtla’s main competitors are Bluebird bio, Inc. (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG).
– Adagio Therapeutics Inc ($NASDAQ:ADGI)
Orphazyme AS is a biotech company that focuses on developing treatments for rare diseases. The company has a market cap of 5.88M as of 2022 and a Return on Equity of -845.21%. Despite its negative ROE, Orphazyme AS’s market cap indicates that investors are confident in the company’s future prospects. This is likely due to the fact that Orphazyme AS is working on developing treatments for rare diseases, which is a highly lucrative market.
Summary
Y-mAbs Therapeutics is a biopharmaceutical company focused on creating innovative therapies for rare and aggressive cancers in children. The company is set to be included in the Nasdaq Biotechnology Index, making it an ideal investment opportunity for investors interested in the biotechnology industry. Investing in Y-mAbs Therapeutics should be approached with cautious optimism, as its therapies are still in early stages of development and have yet to be approved by the FDA.
However, the company has demonstrated promising results in clinical trials and has received various grants and awards that signal a bright future. Investors should do their own research on the company’s current and future products, financials, and competitive landscape before investing. Y-mAbs’ potential to deliver groundbreaking treatments to patients make it an attractive investment opportunity for those seeking long-term growth.
